Ramoplanin
AntibioticAlso known as: Ramoplanin
LipoglycodepsipeptidesResearch phase: Phase 3 (not completed)Regulatory: Not approved. Development stalled after Phase 3.
Mechanism
Ramoplanin is a lipoglycodepsipeptide antibiotic that kills bacteria by blocking cell wall synthesis. It completed Phase 3 trials for preventing C. difficile infection.
Technical detail
Ramoplanin is a cyclic lipoglycodepsipeptide antibiotic that inhibits bacterial transglycosylation by binding to lipid intermediate II (undecaprenyl-pyrophosphoryl-MurNAc-pentapeptide-GlcNAc), blocking peptidoglycan polymerization. It has potent activity against gram-positive organisms including VRE and C. difficile. Phase 3 trials for oral use in C. difficile-associated diarrhea were conducted but development was not completed.